Ravulizumab for treating atypical haemolytic uraemic syndrome - guidance (TA710)

NICE recommends ravulizumab as an option for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more as per outlined criteria and only if the company provides it according to the commercial arrangement.

National Institute for Health and Care Excellence